Tesamorelin is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Phase III 12-month trial (404 HIV patients): 18% visceral fat reduction vs placebo. Two Phase III trials confirmed VAT reduction. FDA-approved November 2010. Newest formulation Egrifta WR approved 2025. Tesamorelin is fda-approved (2010) for hiv-associated lipodystrophy. prescription medication.
What Does the Research Say About Tesamorelin?
Phase III 12-month trial (404 HIV patients): 18% visceral fat reduction vs placebo. Two Phase III trials confirmed VAT reduction. FDA-approved November 2010. Newest formulation Egrifta WR approved 2025.
Tesamorelin (Synthetic GHRH analog (44 amino acid polypeptide)) is a GHRH analog, growth hormone secretagogue. Research interest has focused on its potential effects on visceral fat reduction, body image improvement, metabolic restoration in HIV lipodystrophy.
What Is the Evidence for Tesamorelin's Mechanism?
Activates GHRH receptors on anterior pituitary somatotrophs via cAMP-PKA cascade. Elevated GH drives hepatic IGF-1 production, reducing visceral adiposity through enhanced lipolysis and reduced truncal fat distribution without altering systemic glucose homeostasis.
These pathways have been identified through in vitro studies, animal models, and where available, human trials.
Are There Human Clinical Trials for Tesamorelin?
Phase III 12-month trial (404 HIV patients): 18% visceral fat reduction vs placebo. Two Phase III trials confirmed VAT reduction. FDA-approved November 2010. Newest formulation Egrifta WR approved 2025.
The gap between preclinical promise and clinical validation remains the biggest challenge in peptide research. However, Tesamorelin has shown preliminary results.
What Does the Safety Research Show?
Well-tolerated. Injection site reactions most common. Transient flushing, headache, dizziness possible early on. No significant metabolic derangements.
Tesamorelin is fda-approved (2010) for hiv-associated lipodystrophy. prescription medication.
What Makes Tesamorelin Unique in Research?
The most studied GHRH analog with the longest clinical track record — the only peptide with FDA approval specifically for lipodystrophy-associated visceral fat.
This differentiator is important because it means Tesamorelin fills a role that other compounds in its class may not fully replicate.
Bottom Line on Tesamorelin Research
The evidence base for Tesamorelin is growing. Key research areas include visceral fat reduction, body image improvement, metabolic restoration in HIV lipodystrophy.
Stay current with PubMed searches for Tesamorelin for the latest publications.
Complete Guide
Tesamorelin: The FDA-Approved GHRH Analog
Related Reading
- Tesamorelin Dosage Guide
- Tesamorelin Benefits
- Tesamorelin Side Effects
- Tesamorelin Stacking Guide
- Tesamorelin Cycle Guide
- CJC-1295 Complete Guide
Calculate Your Tesamorelin Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for Tesamorelin.
Open Calculator →Research-Grade Sourcing
If you're going to research Tesamorelin, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is Tesamorelin?
Tesamorelin (Synthetic GHRH analog (44 amino acid polypeptide)) is a GHRH analog, growth hormone secretagogue. Synthetic 44 amino acid GHRH analog with enhanced metabolic stability and DPP-4 protease resistance. It is researched for visceral fat reduction, body image improvement, metabolic restoration in HIV lipodystrophy.
What is the recommended Tesamorelin dosage?
Common dosages: 2 mg daily administered once daily via subcutaneous injection. Cycle length: ongoing maintenance; demonstrated benefit to 12+ months. Half-life: 26-38 minutes. Use our peptide calculator for exact reconstitution math.
What are the side effects of Tesamorelin?
Well-tolerated. Injection site reactions most common. Transient flushing, headache, dizziness possible early on. No significant metabolic derangements.
Is Tesamorelin safe?
Tesamorelin has shown a favorable safety profile in research. FDA-approved (2010) for HIV-associated lipodystrophy. Prescription medication. All research should follow appropriate safety protocols.